Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …

Cancer metabolism is rewired to support cell survival in response to intrinsic and
environmental stressors. Identification of strategies to target these adaptions is an area of …

Long known as terminal degradation stations, lysosomes have emerged as sophisticated
signalling centres that govern cell growth, division and differentiation. Lysosomes interface …

There is a need to develop effective therapies for pancreatic ductal adenocarcinoma (PDA),
a highly lethal malignancy with increasing incidence and poor prognosis. Although targeting …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant infiltration of tumor-
associated macrophages (TAMs). TAMs have been reported to drive resistance to …

Macroautophagy (referred to here as autophagy) is induced by starvation to capture and
degrade intracellular proteins and organelles in lysosomes, which recycles intracellular …

Neoplasms change over time through a process of cell-level evolution, driven by genetic
and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a 5-year
survival rate of< 10%. The tumour microenvironment (TME) of PDAC is characterized by …